** Shares of Aroa Biosurgery ARX.AX rise as much as 3.85% to A$0.675, their highest level since Nov. 13
** NZ's medical products maker posts H1 FY25 loss after tax attributable of NZ$3.3 mln ($1.93 mln), compared to NZ$6.3 mln from a year before
** H1 FY25 revenue from ordinary activities - product sales NZ$39.1 mln, up 25% from a year before
** Co anticipates H2 FY25 total revenue of NZ$43-$50 million
** Expects H2 FY25 normalised EBITDA profit of NZ$4-8 mln
** However stock has fallen 21.7% YTD, as of last close
($1 = 1.7112 New Zealand dollars)
(Reporting by Sherin Sunny in Bengaluru)
((Sherin.Sunny@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。